Oppenheimer analyst Jay Olson maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and maintains the target price at $70.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
The assessment of Intellia Therapeutics' NTLA-2002 Phase 2 data indicated a reduction in attacks, which, while comparable to competitors' Phase 3 trials, was perceived as less impressive compared to the company's Phase 1 outcomes for HAE reported in June. Despite this, analysts still consider the 'one-and-done' treatment approach of NTLA-2002 as a significant differentiator from competitors' treatment frequencies, which range from daily to monthly. The market opportunity for NTLA-2002 remains attractive, though there has been a moderation in the expected peak market share and a more cautious perspective on the success probabilities for NTLA-2001 in ATTR, citing the need for further platform derisking.
The firm has revised its stance slightly more negatively after assessing the Phase 2 study results of NTLA-2002 in patients with hereditary angiodema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Jay Olson維持$Intellia Therapeutics (NTLA.US)$買入評級，維持目標價70美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.6%，總平均回報率為12.4%。
此外，綜合報道，$Intellia Therapeutics (NTLA.US)$近期主要分析師觀點如下：
Intellia Therapeutics的NTLA-2002第2階段數據評估表明，發作減少，雖然與競爭對手的第3階段試驗相當，但與該公司6月份報告的HAE第1階段結果相比，被認爲不太令人印象深刻。儘管如此，分析師仍然認爲NTLA-2002的「一次性」治療方法是與競爭對手治療頻率相比的重要區別，競爭對手的治療頻率從每天到每月不等。NTLA-2002的市場機會仍然具有吸引力，儘管對預期市場份額的峯值有所降低，並且對NTLA-2001在ATTR中成功概率的更謹慎看法，引述需要進一步平台風險降低。
該公司在評估患有遺傳性血管性水腫（HAE）的NTLA-2002患者第2階段研究結果後，將立場稍微調整爲更消極。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
